US20120165302A1 - Antifungal formulations - Google Patents
Antifungal formulations Download PDFInfo
- Publication number
- US20120165302A1 US20120165302A1 US13/349,929 US201213349929A US2012165302A1 US 20120165302 A1 US20120165302 A1 US 20120165302A1 US 201213349929 A US201213349929 A US 201213349929A US 2012165302 A1 US2012165302 A1 US 2012165302A1
- Authority
- US
- United States
- Prior art keywords
- composition
- tinea
- group
- antifungal
- inflammatory
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 0 [1*]C1([2*])O[C@@H]2CC3C4CCC5=CC(=O)C=CC5(C)C4C([4*]O)CC3(C)[C@]2(C(=O)CO[3*])O1 Chemical compound [1*]C1([2*])O[C@@H]2CC3C4CCC5=CC(=O)C=CC5(C)C4C([4*]O)CC3(C)[C@]2(C(=O)CO[3*])O1 0.000 description 3
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/005—Antimicrobial preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
Definitions
- the present invention relates to topical formulations useful for treating fungal diseases, canidiasis, intertriginous dermatitis and their related inflammation.
- the present invention relates to stable topical formulations containing an antifungal agent and an anti-inflammatory steroid.
- LotrisoneTM cream clotrimazole 1%/betamethasone dipropionate 0.064%)
- DaktacortTM cream miconazole nitrate 2%/hydrocortisone 1%)
- CanestenTM HC cream clotrimazole 1%/hydrocortisone 1%
- the steroid component, betamethasone valerate, LotrisoneTM is so strong that it can induce skin atrophy, striae, persistent tinea corporis and even growth retardation in children receiving LotrisoneTM treatment (see, for example, Pediatr. Dermatol. 19(1):78-81 (2002); Cutis 69(1):67-68 (2002); Am. Fam. Physician 65(10:2095-2102 (2002)).
- the remaining two products have only 1% hydrocortisone, which is too low in potency to have significant anti-inflammatory properties.
- a topical composition which contains a low potency anti-inflammatory steroid which is safe and effective as well as an antifungal agent.
- the low potency steroid agent minimizes side effects such as skin atrophy, striae and hypopigmentation.
- the low potency anti-inflammatory steroid has the following structure:
- R 1 , R 2 , R 3 , and R 4 taken independently can be H, C1-C10 alkyl, C1-C10 alkenyl, C3-C10 cycloalkyl, and phenyl groups; R 1 and R 2 taken together can be C3-C10 cycloalkyl; and R 3 , and R 4 taken independently can be H, C1-C10 alkyl, C1-C10 alkenyl, C3-C10 cycloalkyl, phenyl, C7-C10 phenylalkyl, carboxylate, sulfonyl, phosphoryl, and phosphonyl groups.
- the R 1 , R 2 , R 3 , and R 4 groups are independently H, CH 3 , ethyl, propyl, phenyl, and phenylmethyl groups.
- the low potency anti-inflammatory steroid is desonide and the antifungal agent is clotrimazole.
- the composition contains between 0.01 w % and 5.0 wt % desonide and between 0.1 wt % and 5.0 wt % clotrimazole.
- composition can be formulated in any dosage form suitable for topical administration.
- the composition is in a form such as a cream, ointment, gel, lotion, foam, powder, aerosol, spray, shampoo, or liquid solution.
- the composition has a slightly acidic pH in the range, for example, between about 3.5 to about 7.0.
- the composition may further include one or more solvents, emollients, humectants preservatives, emulsifiers, and/or an acid, base, or buffering agent to adjust the pH.
- the composition described herein may optionally contain one or more preservatives. Representative preservatives are benzyl alcohol, sodium benzoate, parabens, and any other preservative useful in drug formulation.
- compositions are useful to treat fungal diseases which are complicated by inflammation, such as tinea pedis, tinea capitis, tinea corporis, tinea versicolor, and tinea cruris.
- yeast diseases such as candididasis and itertriginous dermatitis, in which the disease process, the presence of pathogenic yeast organisms, causes skin disease with resultant inflammation.
- yeast diseases such as candididasis and itertriginous dermatitis, in which the disease process, the presence of pathogenic yeast organisms, causes skin disease with resultant inflammation.
- These conditions, inflammatory tinea, tinea versicolor, and candidiasis associated with dermatitis would respond in an accelerated fashion if both anti fungal/anti-yeast preparations were combined with an anti-inflammatory steroid.
- the resultant compound is applied twice a day to the affected areas.
- a preferred compound would be a combination of desonide cream 0.2% and clotrimazole 1% to be applied thinly to the affected areas twice daily.
- Other non-halogenated or low to medium potency corticosteroids could be substituted for desonide without sacrificing efficacy.
- other antifungals such as econazole could be substituted for clotrimazole.
- Antifungal compositions for treating fungal infections or mycological illnesses include one or more antifungal agents as well as one or more anti-inflammatory agents.
- the composition also contains excipients and a pharmaceutical carrier.
- the useful steroid agents cause reduced side effects such as skin atrophy, perianal ulcers, striae, and skin pigmentary changes.
- antifungal agents A large number of antifungal agents are known in the art. Generally, these can be generally classified into two broad categories, polyene type antifungal agents and azole type antifungal agents.
- Exemplary polyene type antifungal agents are, for example, Amphoterican B, Nystatin, Flucytosin, and Natamycin.
- Exemplary azole type antifungal agents include, for example, Ketoconazole, Econoazole, Miconazole, Itraconazole, Fluconazole, Clotrimazole, Griseofulvin, Oxiconazole, Terconazole, Tioconazole, Clotrimazole, and Silver Sulfadiazine.
- Other representative antifungal agents are, for example, Ciclopirox olamine, Terbinafine, and those disclosed in, for example, U.S. Pat. No. 6,075,056.
- the antifungal agent is an azole type agent such as Clotrimazole.
- the composition includes between 0.01 wt % and 5.0 wt % non-fluorinated corticosteroid.
- the non-fluorinated corticosteroid has the following structure:
- R 1 , R 2 , R 3 , and R 4 taken independently can be H, C1-C10 alkyl, C1-C10 alkenyl, C3-C10 cycloalkyl, and phenyl groups; R 1 and R 2 taken together can be C3-C10 cycloalkyl; and R 3 , and R 4 taken independently can be H, C1-C10 alkyl, C1-C10 alkenyl, C3-C10 cycloalkyl, phenyl, C7-C10 phenylalkyl, carboxylate, sulfonyl, phosphoryl, and phosphonyl groups.
- R 1 , R 2 , R 3 , and R 4 groups are H, CH 3 , ethyl, propyl, phenyl, and phenylmethyl groups.
- the steroid is desonide.
- Desonide is a class 6 nonfluorinated topical corticosteroid which has been available for more than two decades. Clinical trials on desonide showed that desonide is effective and safe for treating children having dermatoses or other skin diseases (see, for example, Cutis 1997 59(3):151-153 (1997); J. Am. Acad. Dermatol. 33(1):74-7 (1995); Brit. J. Dermatol. 131(4):534-40 (1994); and Cutis 18(6):826-30 (1976)).
- composition may alternatively contain one of the following agents in a dosage that causes reduced side effects, Desoximetasone, Mometasone furoate, Triamcinolone acetonide, Triamcinolone acetate, Fluocinolone acetonide, Hydrocortisone valerate, Mometasone furoate, Clocortolone privalate, Fluticasone propionate, Hydrocortisone butyrate, Predincarbate, Aclometasone dipropionate, Desonide, Hydrocortisone probutate
- Hydrocortisone 1% is an OTC preparation with limited anti-inflammatory properties. It would be minimally effective, if effective at all, in treating the significant inflammation that accompanies fungal disease. Desonide is a much higher potency cortisone. It should be effective against more significant degrees of inflammation, as it is prescription only, and because it is non-fluorinated, its safety profile allows it to be used on the face, as well as in intertriginous areas, such as the axilla, the groin, and beneath the breasts, which will be typical areas of application.
- the formulation described herein optionally contains one or more other pharmaceutically active agents.
- Useful agents include any agents commonly used in dermatologic formulations, which may include, but are not limited to, antibacterial agents such as a tetracycline or salicyclic acid (2.0 w/w).
- the pharmaceutically acceptable excipients for topical administration can be a mixture of solvents, emollients, humectants, emulsifiers, and transport enhancer such as natural or synthetic polymer, and lipids.
- Solvents can be, for example, alcohols, esters, propylene glycol, butylene glycol, hexylene glycol, polyethylene glycols, polypropylene glycols, polyurethane compounds, including hydroxy-terminated polyurethanes, in particular polyolprepolymer-2, polyolprepolymer-14, or polyolprepolymer-15.
- Emollients can be, for example, white petrolatum, mineral oil, propylene glycol dicaprylate, lower fatty acid esters and lower alkyl ethers of propylene glycol, cetyl alcohol, cetostearyl alcohol, stearyl alcohol, cetyl esters wax, spermaceti wax, white wax, isopropyl myristate, polyoxyethylene polyoxypropylene cetyl ether, polyoxypropylene methyl glucose ether, polyoxypropylene methyl glucose ether, 2-ethyl-1,3-hexanediol, propylene glycol dioctanoate, methyl gluceth-10, methyl gluceth-20, isodecyl neopentanoate, glycerin, mineral oil, etc.
- Humectants can be, for example, glycerin and sorbitol.
- Emulsifiers can be, for example, glyceryl monostearate, glyceryl monoleate, polyoxyethylene cetyl ether, polyoxyethylene cetostearyl ether, polyoxyethylene stearyl ether, and polyethylene glycol stearate.
- the pH is adjusted where necessary to a pH of about 3.5-7.0, using an acid e.g. hydrochloric acid phosphoric acid, or a base e.g. diethanolamine, triethanolamine, sodium hydroxide, or known buffering agents, e.g. phosphates such as monobasic sodium phosphate, and dibasic sodium phosphate, and citrates well known in the art.
- an acid e.g. hydrochloric acid phosphoric acid
- a base e.g. diethanolamine, triethanolamine, sodium hydroxide
- buffering agents e.g. phosphates such as monobasic sodium phosphate, and dibasic sodium phosphate, and citrates well known in the art.
- a preservative is generally present, for example benzyl alcohol, sodium benzoate, parabens, and the like.
- Representative acids are hydrochloric acid, phosphoric acid, citric acids, and any other acids commonly used in drug formulation.
- Representative bases are diethanolamine, triethanolamine, sodium hydroxide, carbonate, and any other bases suitable for drug formulation.
- Transport enhancers are commonly used in drug formulation to enhance the efficiency of drug delivery.
- U.S. Pat. No. 5,219,877 discloses a vehicle system using lauryl alcohol as skin transport enhancing agent for improved antifungal activity of the drug described therein.
- the vehicle system of these formulations is such that both the antifungal agent and the steroid, if present, are in the solubilized state.
- the vehicle system consists of, in addition to lauryl alcohol, about 10 wt % to 80 wt % of a lower alkanol, such as ethanol and 0 to 40 wt % of a trihydroxy alcohol such as 1,2,6-hexanetriol.
- the vehicle system may be formed into a gel by using 0.1 wt % to 5 wt % of a gelling agent such as hydroxypropylcellulose or hydroxyethylcellulose).
- the formulation may also contain additional materials commonly used in drug formulation, e.g., chelating agents and fragrances.
- the formulations described herein can have various dosage forms.
- the representative dosage forms can be, for example, cream, ointment, gel, lotion, foam, powder, aerosol, spray, shampoo, or liquid solution.
- the formulation can be formulated into other dosages forms suitable for topical application.
- the dosage form is one of cream, ointment, gel and lotion.
- the dosage form is one of foam, powder, aerosol, spray, shampoo, or liquid solution.
- the dosage form is cream, ointment, gel, or lotion.
- the formulation will contain between 0.01 wt % and 5.0 wt % of an antifungal agent and between 0.01 wt % and 5 wt % of an anti-inflammatory steroid agent.
- concentrations of the antifungal agent and the anti-inflammatory steroid can be varied according to the type of the skin conditions, the age of the patients, and the relative strength of the antifungal agents and the anti-inflammatory steroid.
- concentrations of the antifungal agent and the anti-inflammatory steroid can be varied according to the type of the skin conditions, the age of the patients, and the relative strength of the antifungal agents and the anti-inflammatory steroid.
- concentrations of the antifungal agent and the anti-inflammatory steroid can be varied according to the type of the skin conditions, the age of the patients, and the relative strength of the antifungal agents and the anti-inflammatory steroid.
- concentrations of the antifungal agent and the anti-inflammatory steroid can be varied according to the type of the skin conditions, the age of the patients, and
- fragrances and colors may also be added.
- the method using the composition described herein includes administering to a subject in need of treatment the composition in a dosage form of, form example, cream, ointment, gel, lotion, foam, powder, aerosol, spray, shampoo, or liquid solution.
- the dosage form is one of cream, ointment, gel or lotion.
- the dosage form is one of foam, powder, aerosol, spray, shampoo, or liquid solution.
- compositions can be used to treat any fungal disease which is complicated by inflammation.
- the compositions are especially useful to treat fungal diseases such as tinea pedis, tinea capitis, tinea corporis, tinea versicolor, tinea cruris, candidiasis and intertriginous dermatitis complicated by candidiasis.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Birds (AREA)
- Inorganic Chemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
A topical composition and the method using the composition, which contains an antifungal agent and a low potency anti-inflammatory steroid which is safe and effective such as desonide or its derivative. The low potency steroid agent does not cause side effects such as skin atrophy, striae and hypopigmentation. The composition can be formulated in a dosage form such as a cream, ointment, gel, lotion, foam, powder, aerosol, spray, shampoo, or liquid solution. The composition can be used to treat a fungal disease such as tinea pedis, tinea capitis, tinea corporis, tinea versicolor, tinea cruris, and candidiasis as well as intertriginous dermatitis complicated by candidiasis.
Description
- This application claims priority to U.S. Ser. No. 60/421,190, entitled “Antifungal Formulations” filed in the U.S. Patent and Trademark Office on Oct. 24, 2002, by Jay A. Goldstein, Michael Rothman and Whe-Yong Lo.
- The present invention relates to topical formulations useful for treating fungal diseases, canidiasis, intertriginous dermatitis and their related inflammation. In particular, the present invention relates to stable topical formulations containing an antifungal agent and an anti-inflammatory steroid.
- Currently, there is no topical dermatologic preparation that is appropriate for almost all of the skin conditions that are normally seen by pediatricians, internists, and dermatologists. Various formulations based on combinations of anti-fungals and steroids are described in U.S. Pat. Nos. 4,912,124, 5,002,938, 5,021,458, 5,110,809, 5,174,475, 5,219,877, 5,407,663, 5,310,545, 6,075,056, and 6,080,744. The disadvantage of such combinations is that it is undesirable to use fluorinated and/or potent steroids for topical treatment for extended periods of time. Steroids can penetrate the skin and cause undesirable side effects, including skin atrophy, hypopigmentation, suppression of the hypothalamic-pituitary-adrenal axis, Cushing's syndrome, and appearance of telangectasias.
- Several formulations that are commercially available include Lotrisone™ cream (clotrimazole 1%/betamethasone dipropionate 0.064%), Daktacort™ cream (miconazole nitrate 2%/hydrocortisone 1%) and Canesten™ HC cream (clotrimazole 1%/hydrocortisone 1%). The steroid component, betamethasone valerate, Lotrisone™, is so strong that it can induce skin atrophy, striae, persistent tinea corporis and even growth retardation in children receiving Lotrisone™ treatment (see, for example, Pediatr. Dermatol. 19(1):78-81 (2002); Cutis 69(1):67-68 (2002); Am. Fam. Physician 65(10:2095-2102 (2002)). The remaining two products have only 1% hydrocortisone, which is too low in potency to have significant anti-inflammatory properties.
- Therefore, there is no need for a dermatologic formulation that will cause reduced side effects but will still be potent enough for efficacy.
- A topical composition has been developed which contains a low potency anti-inflammatory steroid which is safe and effective as well as an antifungal agent. The low potency steroid agent minimizes side effects such as skin atrophy, striae and hypopigmentation. In a representative example, the low potency anti-inflammatory steroid has the following structure:
- wherein R1, R2, R3, and R4 taken independently can be H, C1-C10 alkyl, C1-C10 alkenyl, C3-C10 cycloalkyl, and phenyl groups; R1 and R2 taken together can be C3-C10 cycloalkyl; and R3, and R4 taken independently can be H, C1-C10 alkyl, C1-C10 alkenyl, C3-C10 cycloalkyl, phenyl, C7-C10 phenylalkyl, carboxylate, sulfonyl, phosphoryl, and phosphonyl groups. Preferably, the R1, R2, R3, and R4 groups are independently H, CH3, ethyl, propyl, phenyl, and phenylmethyl groups. More preferably, the low potency anti-inflammatory steroid is desonide and the antifungal agent is clotrimazole. Most preferably, the composition contains between 0.01 w % and 5.0 wt % desonide and between 0.1 wt % and 5.0 wt % clotrimazole.
- The composition can be formulated in any dosage form suitable for topical administration. Preferably, the composition is in a form such as a cream, ointment, gel, lotion, foam, powder, aerosol, spray, shampoo, or liquid solution.
- The composition has a slightly acidic pH in the range, for example, between about 3.5 to about 7.0. The composition may further include one or more solvents, emollients, humectants preservatives, emulsifiers, and/or an acid, base, or buffering agent to adjust the pH. The composition described herein may optionally contain one or more preservatives. Representative preservatives are benzyl alcohol, sodium benzoate, parabens, and any other preservative useful in drug formulation.
- The compositions are useful to treat fungal diseases which are complicated by inflammation, such as tinea pedis, tinea capitis, tinea corporis, tinea versicolor, and tinea cruris. Other indications are for yeast diseases, such as candididasis and itertriginous dermatitis, in which the disease process, the presence of pathogenic yeast organisms, causes skin disease with resultant inflammation. These conditions, inflammatory tinea, tinea versicolor, and candidiasis associated with dermatitis, would respond in an accelerated fashion if both anti fungal/anti-yeast preparations were combined with an anti-inflammatory steroid. For maximum efficacy, the resultant compound is applied twice a day to the affected areas. A preferred compound would be a combination of desonide cream 0.2% and clotrimazole 1% to be applied thinly to the affected areas twice daily. Other non-halogenated or low to medium potency corticosteroids could be substituted for desonide without sacrificing efficacy. Likewise, other antifungals, such as econazole could be substituted for clotrimazole.
- Antifungal compositions for treating fungal infections or mycological illnesses include one or more antifungal agents as well as one or more anti-inflammatory agents. The composition also contains excipients and a pharmaceutical carrier. The useful steroid agents cause reduced side effects such as skin atrophy, perianal ulcers, striae, and skin pigmentary changes.
- A. Antifungal Agents
- A large number of antifungal agents are known in the art. Generally, these can be generally classified into two broad categories, polyene type antifungal agents and azole type antifungal agents. Exemplary polyene type antifungal agents are, for example, Amphoterican B, Nystatin, Flucytosin, and Natamycin. Exemplary azole type antifungal agents include, for example, Ketoconazole, Econoazole, Miconazole, Itraconazole, Fluconazole, Clotrimazole, Griseofulvin, Oxiconazole, Terconazole, Tioconazole, Clotrimazole, and Silver Sulfadiazine. Other representative antifungal agents are, for example, Ciclopirox olamine, Terbinafine, and those disclosed in, for example, U.S. Pat. No. 6,075,056.
- In a preferred embodiment, the antifungal agent is an azole type agent such as Clotrimazole.
- B. Anti-Inflammatory Agent
- In a representative embodiment, the composition includes between 0.01 wt % and 5.0 wt % non-fluorinated corticosteroid. Preferably, the non-fluorinated corticosteroid has the following structure:
- wherein R1, R2, R3, and R4 taken independently can be H, C1-C10 alkyl, C1-C10 alkenyl, C3-C10 cycloalkyl, and phenyl groups;
R1 and R2 taken together can be C3-C10 cycloalkyl; and
R3, and R4 taken independently can be H, C1-C10 alkyl, C1-C10 alkenyl, C3-C10 cycloalkyl, phenyl, C7-C10 phenylalkyl, carboxylate, sulfonyl, phosphoryl, and phosphonyl groups. - Representative R1, R2, R3, and R4 groups are H, CH3, ethyl, propyl, phenyl, and phenylmethyl groups.
- Most preferably, the steroid is desonide. Desonide is a class 6 nonfluorinated topical corticosteroid which has been available for more than two decades. Clinical trials on desonide showed that desonide is effective and safe for treating children having dermatoses or other skin diseases (see, for example, Cutis 1997 59(3):151-153 (1997); J. Am. Acad. Dermatol. 33(1):74-7 (1995); Brit. J. Dermatol. 131(4):534-40 (1994); and Cutis 18(6):826-30 (1976)).
- The composition may alternatively contain one of the following agents in a dosage that causes reduced side effects, Desoximetasone, Mometasone furoate, Triamcinolone acetonide, Triamcinolone acetate, Fluocinolone acetonide, Hydrocortisone valerate, Mometasone furoate, Clocortolone privalate, Fluticasone propionate, Hydrocortisone butyrate, Predincarbate, Aclometasone dipropionate, Desonide, Hydrocortisone probutate
- Hydrocortisone 1% is an OTC preparation with limited anti-inflammatory properties. It would be minimally effective, if effective at all, in treating the significant inflammation that accompanies fungal disease. Desonide is a much higher potency cortisone. It should be effective against more significant degrees of inflammation, as it is prescription only, and because it is non-fluorinated, its safety profile allows it to be used on the face, as well as in intertriginous areas, such as the axilla, the groin, and beneath the breasts, which will be typical areas of application.
- C. Other Bioactive Agents
- The formulation described herein optionally contains one or more other pharmaceutically active agents. Useful agents include any agents commonly used in dermatologic formulations, which may include, but are not limited to, antibacterial agents such as a tetracycline or salicyclic acid (2.0 w/w).
- D. Excipients
- The pharmaceutically acceptable excipients for topical administration can be a mixture of solvents, emollients, humectants, emulsifiers, and transport enhancer such as natural or synthetic polymer, and lipids.
- Solvents can be, for example, alcohols, esters, propylene glycol, butylene glycol, hexylene glycol, polyethylene glycols, polypropylene glycols, polyurethane compounds, including hydroxy-terminated polyurethanes, in particular polyolprepolymer-2, polyolprepolymer-14, or polyolprepolymer-15. Emollients can be, for example, white petrolatum, mineral oil, propylene glycol dicaprylate, lower fatty acid esters and lower alkyl ethers of propylene glycol, cetyl alcohol, cetostearyl alcohol, stearyl alcohol, cetyl esters wax, spermaceti wax, white wax, isopropyl myristate, polyoxyethylene polyoxypropylene cetyl ether, polyoxypropylene methyl glucose ether, polyoxypropylene methyl glucose ether, 2-ethyl-1,3-hexanediol, propylene glycol dioctanoate, methyl gluceth-10, methyl gluceth-20, isodecyl neopentanoate, glycerin, mineral oil, etc. (preferably in an amount of up to about 40 wt %, more preferably about 5 to 30 wt %). Humectants can be, for example, glycerin and sorbitol. Emulsifiers can be, for example, glyceryl monostearate, glyceryl monoleate, polyoxyethylene cetyl ether, polyoxyethylene cetostearyl ether, polyoxyethylene stearyl ether, and polyethylene glycol stearate.
- The pH is adjusted where necessary to a pH of about 3.5-7.0, using an acid e.g. hydrochloric acid phosphoric acid, or a base e.g. diethanolamine, triethanolamine, sodium hydroxide, or known buffering agents, e.g. phosphates such as monobasic sodium phosphate, and dibasic sodium phosphate, and citrates well known in the art. A preservative is generally present, for example benzyl alcohol, sodium benzoate, parabens, and the like.
- Representative acids are hydrochloric acid, phosphoric acid, citric acids, and any other acids commonly used in drug formulation. Representative bases are diethanolamine, triethanolamine, sodium hydroxide, carbonate, and any other bases suitable for drug formulation.
- Other excipients described in U.S. Pat. Nos. 4,912,124, 5,002,938, 5,021,458, 5,110,809, 5,174,475, 5,219,877, 5,310,545, 5,407,663, 6,075,056, and 6,080,744 are also useful for forming the composition described herein. For example, U.S. Pat. No. 4,912,124 describes a polar solvent system formed of ethanol and water.
- Transport enhancers are commonly used in drug formulation to enhance the efficiency of drug delivery. For example, U.S. Pat. No. 5,219,877 discloses a vehicle system using lauryl alcohol as skin transport enhancing agent for improved antifungal activity of the drug described therein. The vehicle system of these formulations is such that both the antifungal agent and the steroid, if present, are in the solubilized state. The vehicle system consists of, in addition to lauryl alcohol, about 10 wt % to 80 wt % of a lower alkanol, such as ethanol and 0 to 40 wt % of a trihydroxy alcohol such as 1,2,6-hexanetriol. The vehicle system may be formed into a gel by using 0.1 wt % to 5 wt % of a gelling agent such as hydroxypropylcellulose or hydroxyethylcellulose).
- The formulation may also contain additional materials commonly used in drug formulation, e.g., chelating agents and fragrances.
- The formulations described herein can have various dosage forms. The representative dosage forms can be, for example, cream, ointment, gel, lotion, foam, powder, aerosol, spray, shampoo, or liquid solution. The formulation can be formulated into other dosages forms suitable for topical application. In one embodiment, the dosage form is one of cream, ointment, gel and lotion. In another embodiment, the dosage form is one of foam, powder, aerosol, spray, shampoo, or liquid solution. Preferably, the dosage form is cream, ointment, gel, or lotion.
- Generally, the formulation will contain between 0.01 wt % and 5.0 wt % of an antifungal agent and between 0.01 wt % and 5 wt % of an anti-inflammatory steroid agent. The concentrations of the antifungal agent and the anti-inflammatory steroid can be varied according to the type of the skin conditions, the age of the patients, and the relative strength of the antifungal agents and the anti-inflammatory steroid. One of ordinary skill in the art would be able to choose an appropriate concentration for use in an appropriate age group for a particular infection.
- Other additives such as fragrances and colors may also be added.
- Generally, the method using the composition described herein includes administering to a subject in need of treatment the composition in a dosage form of, form example, cream, ointment, gel, lotion, foam, powder, aerosol, spray, shampoo, or liquid solution. In one embodiment, the dosage form is one of cream, ointment, gel or lotion. In another embodiment, the dosage form is one of foam, powder, aerosol, spray, shampoo, or liquid solution.
- The compositions can be used to treat any fungal disease which is complicated by inflammation. The compositions are especially useful to treat fungal diseases such as tinea pedis, tinea capitis, tinea corporis, tinea versicolor, tinea cruris, candidiasis and intertriginous dermatitis complicated by candidiasis.
Claims (14)
1-16. (canceled)
17. A topical antifungal composition comprising:
a) a therapeutically effective amount of an azole-containing antifungal compound for treating a fungal disease or a pharmaceutically acceptable salt thereof; and
b) a therapeutically effective amount of a low to low-medium potency steroidal anti-inflammatory causing minimal skin atrophy, striae and hypopigmentation, in a concentration between 0.01 wt % and 5.0 wt %, and having a higher potency than 1 wt % hydrocortisone, and
c) a carrier suitable for administration of the antifungal compound and the steroidal anti-inflammatory to the skin, wherein the composition does not cause the steroids to penetrate the skin and cause undesirable local side effects.
18. The antifungal composition of claim 17 wherein the steroidal anti-inflammatory has the following structure:
wherein R1, R2, R3, and R4 taken independently can be H, C1-C10 alkyl, C1-C10 alkenyl, C3-C10 cycloalkyl, and phenyl groups; R1 and R2 taken together can be C3-C10 cycloalkyl; and R3 and R4 taken independently can be H, C1-C10 alkyl, C1-C10 alkenyl, C3-C10 cycloalkyl, phenyl, C7-C10 phenylalkyl, carboxylate, sulfonyl, phosphoryl, and phosphonyl groups.
19. The composition of claim 18 wherein R1, R2, R3, and R4 groups are independently H, CH3, ethyl, propyl, phenyl, and phenylmethyl groups.
20. The composition of claim 17 wherein the steroidal anti-inflammatory is selected from the group consisting of Fluocinolone acetonide, Hydrocortisone valerate, Hydrocortisone butyrate, Alclometasone dipropionate, Desonide, and hydrocortisone probutate.
21. The composition of claim 17 wherein the antifungal is selected from the group consisting of Ketoconazole, Econoazole, Miconazole, Itraconazole, Fluconazole, Econazole, Clotrimazole, Oxiconazole, Terconazole, Tioconazole, and Clotrimazole.
22. The composition of claim 17 , wherein the composition is formulated as a cream, ointment, gel, lotion, foam, powder, aerosol, spray, shampoo, or liquid solution.
23. The composition of claim 17 having a pH of about 3.5 to about 7.0 further comprising: at least one solvent, at least one emollient, at least one humectant, at least one preservative, and at least one emulsifier; and optionally including an acid, base, or buffering agent to adjust the pH.
24. The composition of claim 23 , wherein the solvent is selected from the group consisting of propylene glycol, butylene glycol, hexylene glycol, polyethylene glycols, polypropylene glycols, and polyurethane compounds; the emollient is selected from the group consisting of white petrolatum, mineral oil, propylene glycol dicaprylate, lower fatty acid esters and lower alkyl ethers of propylene glycol, cetyl alcohol, cetostearyl alcohol, stearyl alcohol, stearic acid, cetyl esters wax, spermaceti wax, and white wax; the humectant is selected from the group consisting of glycerin and sorbitol; and the emulsifier is selected from the group consisting of glyceryl monostearate, glyceryl monoleate, stearic acid, polyoxyethylene cetyl ether, polyoxyethylene cetostearyl ether, polyoxyethylene stearyl ether, and polyethylene glycol stearate; wherein the optional acid is selected from the group consisting of hydrochloric acid and phosphoric acid, the optional base is chosen from diethanolamine, triethanolamine, and sodium hydroxide, the optional buffering agent is chosen from monobasic sodium phosphate and dibasic sodium phosphate, and the preservative is chosen from benzyl alcohol, sodium benzoate and parabens.
25. The composition of claim 17 wherein the antifungal is in an amount effective to treat fungal disease selected from the group consisting of tinea pedis, tinea capitis, tinea corporis, tinea versicolor, scalp disorders, tinea cruris, and candidiasis.
26. A method of treating a fungal disease comprising administering to a subject in need of treatment the composition of any of claim 17 , with a thin application of the composition two times per day to the affected areas.
27. The method of claim 26 wherein the subject is a child of under 10 years old.
28. The method of claim 26 wherein the fungal disease is selected from the group consisting of tinea pedis, tinea capitis, tinea corporis, tinea versicolor, scalp disorders, tinea cruris, and candidiasis.
29. The composition of claim 17 wherein the steroidal anti-inflammatory is not halogenated.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/349,929 US20120165302A1 (en) | 2002-10-24 | 2012-01-13 | Antifungal formulations |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US42119002P | 2002-10-24 | 2002-10-24 | |
US10/691,928 US8232304B2 (en) | 2002-10-24 | 2003-10-23 | Antifungal formulations |
US13/349,929 US20120165302A1 (en) | 2002-10-24 | 2012-01-13 | Antifungal formulations |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/691,928 Continuation US8232304B2 (en) | 2002-10-24 | 2003-10-23 | Antifungal formulations |
Publications (1)
Publication Number | Publication Date |
---|---|
US20120165302A1 true US20120165302A1 (en) | 2012-06-28 |
Family
ID=32176679
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/691,928 Active 2029-05-15 US8232304B2 (en) | 2002-10-24 | 2003-10-23 | Antifungal formulations |
US13/349,929 Abandoned US20120165302A1 (en) | 2002-10-24 | 2012-01-13 | Antifungal formulations |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/691,928 Active 2029-05-15 US8232304B2 (en) | 2002-10-24 | 2003-10-23 | Antifungal formulations |
Country Status (5)
Country | Link |
---|---|
US (2) | US8232304B2 (en) |
EP (1) | EP1567113A4 (en) |
AU (1) | AU2003301516A1 (en) |
CA (1) | CA2528776A1 (en) |
WO (1) | WO2004037197A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113413363A (en) * | 2021-08-12 | 2021-09-21 | 福元药业有限公司 | Desonide cream and preparation method thereof |
Families Citing this family (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8512718B2 (en) | 2000-07-03 | 2013-08-20 | Foamix Ltd. | Pharmaceutical composition for topical application |
WO2004037225A2 (en) | 2002-10-25 | 2004-05-06 | Foamix Ltd. | Cosmetic and pharmaceutical foam |
IL152486A0 (en) | 2002-10-25 | 2003-05-29 | Meir Eini | Alcohol-free cosmetic and pharmaceutical foam carrier |
EP1567113A4 (en) * | 2002-10-24 | 2006-11-08 | G & R Pharmaceuticals Llc | Antifungal formulations |
US9668972B2 (en) | 2002-10-25 | 2017-06-06 | Foamix Pharmaceuticals Ltd. | Nonsteroidal immunomodulating kit and composition and uses thereof |
US9211259B2 (en) | 2002-11-29 | 2015-12-15 | Foamix Pharmaceuticals Ltd. | Antibiotic kit and composition and uses thereof |
US7700076B2 (en) | 2002-10-25 | 2010-04-20 | Foamix, Ltd. | Penetrating pharmaceutical foam |
US8119150B2 (en) | 2002-10-25 | 2012-02-21 | Foamix Ltd. | Non-flammable insecticide composition and uses thereof |
US7704518B2 (en) | 2003-08-04 | 2010-04-27 | Foamix, Ltd. | Foamable vehicle and pharmaceutical compositions thereof |
US10117812B2 (en) | 2002-10-25 | 2018-11-06 | Foamix Pharmaceuticals Ltd. | Foamable composition combining a polar solvent and a hydrophobic carrier |
US8900554B2 (en) | 2002-10-25 | 2014-12-02 | Foamix Pharmaceuticals Ltd. | Foamable composition and uses thereof |
US7820145B2 (en) | 2003-08-04 | 2010-10-26 | Foamix Ltd. | Oleaginous pharmaceutical and cosmetic foam |
US9265725B2 (en) | 2002-10-25 | 2016-02-23 | Foamix Pharmaceuticals Ltd. | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof |
US8119109B2 (en) | 2002-10-25 | 2012-02-21 | Foamix Ltd. | Foamable compositions, kits and methods for hyperhidrosis |
US20080138296A1 (en) | 2002-10-25 | 2008-06-12 | Foamix Ltd. | Foam prepared from nanoemulsions and uses |
US8486376B2 (en) | 2002-10-25 | 2013-07-16 | Foamix Ltd. | Moisturizing foam containing lanolin |
US7575739B2 (en) | 2003-04-28 | 2009-08-18 | Foamix Ltd. | Foamable iodine composition |
US8795693B2 (en) | 2003-08-04 | 2014-08-05 | Foamix Ltd. | Compositions with modulating agents |
US8486374B2 (en) | 2003-08-04 | 2013-07-16 | Foamix Ltd. | Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses |
US7854943B2 (en) * | 2004-06-24 | 2010-12-21 | Idexx Laboratories | Phospholipid gel compositions for drug delivery and methods of treating conditions using same |
US7618651B2 (en) * | 2004-06-24 | 2009-11-17 | Idexx Laboratories | Pharmaceutical compositions for drug delivery and methods of treating or preventing conditions using same |
US7858115B2 (en) * | 2004-06-24 | 2010-12-28 | Idexx Laboratories | Phospholipid gel compositions for drug delivery and methods of treating conditions using same |
US20080260655A1 (en) | 2006-11-14 | 2008-10-23 | Dov Tamarkin | Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses |
US8636982B2 (en) | 2007-08-07 | 2014-01-28 | Foamix Ltd. | Wax foamable vehicle and pharmaceutical compositions thereof |
MX2010005861A (en) | 2007-11-30 | 2010-06-11 | Pfizer Ltd | Novel glucocorticoid receptor agonists. |
WO2009069006A2 (en) | 2007-11-30 | 2009-06-04 | Foamix Ltd. | Foam containing benzoyl peroxide |
WO2010041141A2 (en) | 2008-10-07 | 2010-04-15 | Foamix Ltd. | Oil-based foamable carriers and formulations |
WO2009090495A2 (en) | 2007-12-07 | 2009-07-23 | Foamix Ltd. | Oil and liquid silicone foamable carriers and formulations |
CA2712120A1 (en) | 2008-01-14 | 2009-07-23 | Foamix Ltd. | Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses |
WO2010125470A2 (en) | 2009-04-28 | 2010-11-04 | Foamix Ltd. | Foamable vehicle and pharmaceutical compositions comprising aprotic polar solvents and uses thereof |
CA2769677A1 (en) | 2009-07-29 | 2011-02-03 | Foamix Ltd. | Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses |
WO2011013009A2 (en) | 2009-07-29 | 2011-02-03 | Foamix Ltd. | Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses |
WO2011064631A1 (en) | 2009-10-02 | 2011-06-03 | Foamix Ltd. | Surfactant-free, water-free, foamable compositions and breakable foams and their uses |
US9849142B2 (en) | 2009-10-02 | 2017-12-26 | Foamix Pharmaceuticals Ltd. | Methods for accelerated return of skin integrity and for the treatment of impetigo |
US8174881B2 (en) | 2009-11-24 | 2012-05-08 | Micron Technology, Inc. | Techniques for reducing disturbance in a semiconductor device |
SI2575477T1 (en) | 2010-05-05 | 2020-10-30 | Stockton (Israel) Ltd. | Combinations of antifungal compounds and tea tree oil |
CN103070911A (en) * | 2012-05-31 | 2013-05-01 | 张旭 | Foot fungus beriberi treatment powder |
CN102716156A (en) * | 2012-06-22 | 2012-10-10 | 吴长宇 | External sterilization antiphlogistine formula and method for preparing antiphlogistine |
JP6194003B2 (en) | 2012-10-09 | 2017-09-06 | ザ プロクター アンド ギャンブル カンパニー | Method for identifying or evaluating beneficial agent and composition containing the same |
JP6189962B2 (en) | 2012-10-09 | 2017-08-30 | ザ プロクター アンド ギャンブル カンパニー | How to identify synergistic cosmetic ingredient combinations |
CN102988609A (en) * | 2012-11-29 | 2013-03-27 | 启东市隆腾电气有限公司 | Anti-inflammatory medicament |
US8936814B2 (en) | 2012-11-30 | 2015-01-20 | Zuri A. Murrell | Skin cream |
CN103083502A (en) * | 2013-01-15 | 2013-05-08 | 西北农林科技大学 | Drug for treating animal traumatic infection disease |
US9138393B2 (en) | 2013-02-08 | 2015-09-22 | The Procter & Gamble Company | Cosmetic compositions containing substituted azole and methods for improving the appearance of aging skin |
US9144538B2 (en) | 2013-02-08 | 2015-09-29 | The Procter & Gamble Company | Cosmetic compositions containing substituted azole and methods for alleviating the signs of photoaged skin |
US9303060B1 (en) * | 2014-10-03 | 2016-04-05 | Amphaster Pharmaceuticals, Inc. | Methods of preparing intermediate of fluticasone propionate |
US11793783B2 (en) | 2015-08-05 | 2023-10-24 | Cmpd Licensing, Llc | Compositions and methods for treating an infection |
US11684567B2 (en) | 2015-08-05 | 2023-06-27 | Cmpd Licensing, Llc | Compositions and methods for treating an infection |
CA3025377A1 (en) | 2016-06-02 | 2017-12-07 | Abbvie Inc. | Glucocorticoid receptor agonist and immunoconjugates thereof |
US10398641B2 (en) | 2016-09-08 | 2019-09-03 | Foamix Pharmaceuticals Ltd. | Compositions and methods for treating rosacea and acne |
PE20201286A1 (en) | 2017-12-01 | 2020-11-24 | Abbvie Inc | GLUCOCORTICOID RECEPTOR AGONIST AND IMMUNOCONJUGATES OF THIS |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5654293A (en) * | 1993-01-21 | 1997-08-05 | Janssen Pharmaceutica N.V. | Topical oil-in-water emulsion compositions containing ketoconazole and an acetonide glucocorticosteroid |
US5985319A (en) * | 1993-09-08 | 1999-11-16 | Edko Trading And Representation Company Limited | Multi-phase compositions for an initial and delayed release of a vaginal medicament |
US20040157936A1 (en) * | 1998-12-04 | 2004-08-12 | Johnson And Johnson Consumer Companies Inc. | Anhydrous topical skin preparations |
US8232304B2 (en) * | 2002-10-24 | 2012-07-31 | G & R Pharmaceuticals, Llc | Antifungal formulations |
US20120270835A1 (en) * | 2009-04-13 | 2012-10-25 | Apex Laboratories Private Limited | Medicinal Cream Made Using Hydrocortisone Acetate and A Process To Make The Same |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4912124A (en) | 1984-02-23 | 1990-03-27 | Ortho Pharmaceutical Corporation | Antifungal dermatological solution |
JPS6145A (en) | 1984-06-09 | 1986-01-06 | Kaken Pharmaceut Co Ltd | Naphthylmethylamine derivative and antifungal containing the same |
US4895727A (en) * | 1985-05-03 | 1990-01-23 | Chemex Pharmaceuticals, Inc. | Pharmaceutical vehicles for exhancing penetration and retention in the skin |
US5110809A (en) * | 1988-03-21 | 1992-05-05 | Bristol-Myers Squibb Company | Antifungal gel formulations |
US5002938A (en) * | 1988-03-21 | 1991-03-26 | Bristol-Myers Squibb Company | Antifungal gel formulations |
US5219877A (en) * | 1989-09-25 | 1993-06-15 | Bristol-Myers Squibb Company | Lauryl alcohol as skin penetration enhancer for topical imidazole agents |
US5174475A (en) | 1991-03-26 | 1992-12-29 | Glaxo Inc. | Sequential dosing of antifungal and antiinflammatory compositions |
US5310545A (en) | 1991-04-11 | 1994-05-10 | Drore Eisen | Method of treatment using mouthwashes containing steroids and antifungal agents and compositions of matter |
US5407663A (en) | 1991-04-11 | 1995-04-18 | Eisen; Drore | Method of treating inflammatory conditions of the mouth using steroid containing mouthwash which may contain antifungal agents |
EP0579760A4 (en) | 1991-04-11 | 1995-07-05 | Drore Eisen | Method of treatment using steroid mouthwash. |
KR100282575B1 (en) * | 1992-02-07 | 2001-02-15 | 알버트엠.클릭만 | Pharmaceutical composition for treating inflammatory skin disease |
EP0735861A1 (en) * | 1993-12-23 | 1996-10-09 | The Procter & Gamble Company | Tissue moisturizing and antimicrobial compositions |
US5977176A (en) * | 1995-06-27 | 1999-11-02 | Wise; Ronald D. | Compositions for the treatment of warts and herpes |
US6075056A (en) * | 1997-10-03 | 2000-06-13 | Penederm, Inc. | Antifungal/steroid topical compositions |
US6238683B1 (en) * | 1998-12-04 | 2001-05-29 | Johnson & Johnson Consumer Companies, Inc. | Anhydrous topical skin preparations |
US6080744A (en) | 1999-02-10 | 2000-06-27 | Ayon-Covarrubias; Blas | Topical antifungal treatment |
US6444647B1 (en) * | 1999-04-19 | 2002-09-03 | The Procter & Gamble Company | Skin care compositions containing combination of skin care actives |
US6656928B1 (en) * | 1999-09-02 | 2003-12-02 | Mccadden Michael E. | Composition for the topical treatment of rashes, dermatoses and lesions |
US6395721B1 (en) * | 2000-01-05 | 2002-05-28 | Leonard Bloom | Low potency unpreserved sterile topical corticosteroid compositions for dermatitis |
CA2345501A1 (en) | 2000-05-01 | 2001-11-01 | Johnson & Johnson Consumer Companies, Inc. | Anhydrous topical skin preparations |
ATE536185T1 (en) * | 2001-03-26 | 2011-12-15 | Dana Farber Cancer Inst Inc | METHOD FOR ATTENUATE REACTIONS TO SKIN IRRITANTS |
-
2003
- 2003-10-23 EP EP03809628A patent/EP1567113A4/en not_active Withdrawn
- 2003-10-23 AU AU2003301516A patent/AU2003301516A1/en not_active Abandoned
- 2003-10-23 WO PCT/US2003/033693 patent/WO2004037197A2/en not_active Application Discontinuation
- 2003-10-23 CA CA002528776A patent/CA2528776A1/en not_active Abandoned
- 2003-10-23 US US10/691,928 patent/US8232304B2/en active Active
-
2012
- 2012-01-13 US US13/349,929 patent/US20120165302A1/en not_active Abandoned
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5654293A (en) * | 1993-01-21 | 1997-08-05 | Janssen Pharmaceutica N.V. | Topical oil-in-water emulsion compositions containing ketoconazole and an acetonide glucocorticosteroid |
US5985319A (en) * | 1993-09-08 | 1999-11-16 | Edko Trading And Representation Company Limited | Multi-phase compositions for an initial and delayed release of a vaginal medicament |
US20040157936A1 (en) * | 1998-12-04 | 2004-08-12 | Johnson And Johnson Consumer Companies Inc. | Anhydrous topical skin preparations |
US8232304B2 (en) * | 2002-10-24 | 2012-07-31 | G & R Pharmaceuticals, Llc | Antifungal formulations |
US20120270835A1 (en) * | 2009-04-13 | 2012-10-25 | Apex Laboratories Private Limited | Medicinal Cream Made Using Hydrocortisone Acetate and A Process To Make The Same |
Non-Patent Citations (3)
Title |
---|
Aditya K. Gupta, R. Gary Sibbald, Charles W. Lynde, Peter R. Hull, Ronald Prussick, Neil H. Shear, Piet De Doncker, C. Ralph Daniel HI and Boni E. Elewski, "Onychomycosis in children: Prevalence and treatment strategies", Journal of the American Academy of Dermatology 1997;36:395-402. * |
DermNet NZ, "Corticosteroids", 2008, obtained from the web at dermnetnz.org/doctors/dermatitis/corticosteroids.html. * |
J.F.STALDER, M.FLEURY, M.SOURISSE, M.ROSTIN, F.PHELINE AND P.LITOUX, "Local steroid therapy and bacterial skin flora in atopic dermatitis", British Journal of Dermatology (1994) 131, 536-540 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113413363A (en) * | 2021-08-12 | 2021-09-21 | 福元药业有限公司 | Desonide cream and preparation method thereof |
Also Published As
Publication number | Publication date |
---|---|
CA2528776A1 (en) | 2004-05-06 |
WO2004037197A2 (en) | 2004-05-06 |
EP1567113A2 (en) | 2005-08-31 |
AU2003301516A8 (en) | 2004-05-13 |
EP1567113A4 (en) | 2006-11-08 |
AU2003301516A1 (en) | 2004-05-13 |
US8232304B2 (en) | 2012-07-31 |
US20040138179A1 (en) | 2004-07-15 |
WO2004037197A3 (en) | 2004-07-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8232304B2 (en) | Antifungal formulations | |
EP1051193B1 (en) | Anhydrous topical skin preparation comprising ketoconazole | |
US5110809A (en) | Antifungal gel formulations | |
US5219877A (en) | Lauryl alcohol as skin penetration enhancer for topical imidazole agents | |
US5002938A (en) | Antifungal gel formulations | |
US6075056A (en) | Antifungal/steroid topical compositions | |
US8735393B2 (en) | Anhydrous topical skin preparations | |
EP0362270B2 (en) | Steroid lotion | |
JP2555555B2 (en) | Antifungal topical formulation | |
EP0573492B1 (en) | Compositions for topical administration containing fluticasone propionate and oxiconazole or its salts | |
US20080166398A1 (en) | Antifungal Compositions | |
US5208015A (en) | Topical anti-fungal agents having anti-inflammatory activity | |
US4489071A (en) | Betamethasone dipropionate cream | |
CA1049409A (en) | Preparation of steroid-neomycin topical composition | |
JPH09176014A (en) | Antimycotic composition for external use | |
NZ235054A (en) | Gel formulation comprising imidazole antifungal agent and a 17-ester steroid anti-inflammatory agent with a co-solvent system and a gelling agent | |
EP1159956B1 (en) | Anhydrous topical skin preparations | |
US5879711A (en) | Stable antiandrogenic gel composition | |
JPH09208464A (en) | Antimycotic composition for external use | |
CA1319105C (en) | Antifungal gel formulations | |
JP2009167139A (en) | External use composition | |
WO2017091168A1 (en) | A topical spray comprising isoconazole nitrate and difluocortolone valerate | |
KR19990014956A (en) | Medicinal pack composition and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |